High dose chemotherapy: Rationale and results in breast carcinoma

Cancer

Volumn 88, Issue 12 SUPPL., 2000, Pages 3059-3064

  Coleman, Robert E ^a  

^a WESTON PARK HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ANTHRACYCLINE DERIVATIVE; CARBOPLATIN; CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; METHOTREXATE; MITOXANTRONE; MYELOABLATIVE AGENT; TAXANE DERIVATIVE; THIOTEPA;

ADVANCED CANCER; BREAST CARCINOMA; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER SURVIVAL; CLINICAL TRIAL; CONFERENCE PAPER; DRUG MEGADOSE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; MULTIMODALITY CANCER THERAPY; PRIORITY JOURNAL; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0034659930     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0142(20000615)88:12+<3059::aid-cncr24>3.0.co;2-h     Document Type: Conference Paper

References (23)

1. Frei E III, Canellos GP. Dose: a critical factor in cancer chemotherapy. Am J Med 1980:69;585-93.
2. Antman K, Souhami RL. High dose chemotherapy in solid tumours. Ann Oncol 1983;4:S29-S44.
3. Bonnadonna G, Valagussa P. Dose-response effect of adjuvant chemotherapy in breast cancer. N Engl J Med 1981:304;10-5.
4. Hryniuk W, Bush H. The importance of dose intensity in chemotherapy of metastatic breast cancer. J Clin Oncol 1984:2;1281-8.
5. Henderson IC, Hayes DF, Gelman R. Dose response in the treatment of breast cancer. J Clin Oncol 1988:6;1501-15.
6. Clemons M, Gharif R, Howell A. The value of dose intensification of standard chemotherapy for advanced breast cancer using colony-stimulating factors alone. Cancer Treat Rev 1998:24;173-84.
7. Rahman ZU, Hortobagyi GN, Buzdar AU, Champlin R. High dose chemotherapy with autologous stem cell support in patients with breast cancer. Cancer Treat Rev 1998:24;249-63.
8. Greenberg PA, Hortobagyi GN, Smith TL, Ziegler LD, Frye DK, Buzdar AU. Long term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 1996:14;2197-205.
9. Early Breast Cancer Trialists Collaborative Group. Polychemotherapy for early breast cancer: an overview of the randomized trials. Lancet 1998;352:930.
10. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
11. Wood WC, Budman DR, Korzun AH, Cooper MR, Younger J, Hart RD, et al. Dose and dose intensity of adjuvant chemotherapy for stage II node positive breast cancer. N Engl J Med 1994;330:1253-9.
12. Henderson IC, Berry D, Demetri G, Cirrincione C, Goldstein L, et al. Improved disease-free and overall survival from the addition of sequential paclitaxel but not from the escalation of doxorubicin dose level in the adjuvant chemotherapy of patients with node positive breast cancer. ASCO Proc 1998; 17:101a.
13. Fisher B, Anderson S, Wickerham D, Decillis A, Dimitrov N, et al. Increased intensification and total dose of cyclophosphamide in a doxorubicin-cyclophosphamide regimen for the treatment of primary breast cancer. Findings from NSABP B-22. J Clin Oncol 1997;15:1858.
14. Levine M, Bramwell V, Pritchard K, Norris BD, Shepherd LE, Abu-Zahra H, et al. Randomised trial of intensive cyclophosphamide, epirubicin and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 1998;16:2651-8.
15. Bezwoda WR, Seymour L, Dansey RD. High dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomised trial. J Clin Oncol 1995;13:2483-9.
16. Stadtmauer EA, O'Neill A, Goldstein L, Crilley P, Mangan K, Ingle J, et al. Phase III randomized trial of high-dose chemotherapy (HDC) and stem cell support (SCT) shows no difference in overall survival or severe toxicity compared to maintenance chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) for women with metastatic breast cancer who are responding to conventional induction chemotherapy: the Philadelphia Intergroup Study (PBT-1). ASCO Proc 1999:18;1a.
17. Lotz J-P, Cure H, Janvier M, Morvan F, Asselain B, Guillemot M, et al. High-dose chemotherapy (HD-CT) with hematopoietic stem cells transplantation (HSCT) for metastatic breast cancer (MBC): results of the French Protocol PEGASE 04. ASCO Proc 1999:18;161a.
18. Scandinavian Breast Cancer Study Group 9401. Results fom a randomised adjuvant breast cancer study with high dose chemotherapy with CTCb supported by autologous bone marrow stem cells versus dose escalated and tailored FEC therapy. ASCO Proc 1999:18;3a.
19. Peters W, Rosner G Vredenburgh J, Shpall E, Crump M, et al. A prospective randomised comparison of two doses of combination alkylating agents as consolidation after CAF in high risk primary breast cancer involving ten or more axillary lymph nodes: preliminary results of CALGB 9082/SWOG 9114 /NCIC-13. ASCO Proc 1999:18;2a.
20. Rodenhuis S, Richel DJ, van der Wall E, Schornagel JH, Baars JW, Koning CC, et al. Randomised trial of high dose chemotherapy and haematopoetic progenitor cell support in operable breast cancer with extensive axillary lymph node involvement. Lancet 1998:352;515-21.
21. Hortobagyi GN, Buzdar AU, Champlin RE, Gajewski J, Holmes FA, Booser D, et al. Lack of efficacy of adjuvant high-dose (HD) tandem combination chemotherapy (CT) for high-risk primary breast cancer (HRPBC) - a randomized trial. ASCO Proc 1998;17:471a.
22. Bezwoda WR. Randomised controlled trial of high dose chemotherapy (HD-CNVp) versus standard CAF chemotherapy for high risk, surgically treated, primary breast cancer. ASCO Proc 1999:18;4a.
23. Berger A. High dose chemotherapy offers little benefit in breast cancer. BMJ 1999:318;1440.